[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367809-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367809-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","emerging-nanotherapeutics-for-hpv-associated-cancers-current-advances-challenges-and-future-directions","Emerging nanotherapeutics for HPV-associated cancers: current advances, challenges, and future directions","","Human Papillomavirus (HPV) is a prevalent sexually transmitted infection that contributes to about 5% of total cancer cases, including cervical, vulvar, vaginal, penile, anal, oral, and oropharyngeal cancers. Conventional treatments such as surgery, chemotherapy, and radiotherapy can be limited by non-specificity and harmful effects on non-tumor cells. Nanotherapeutics enable more precise targeting and drug delivery, and can be integrated with gene therapy or immunotherapy. This review synthesizes PubMed and Scopus findings and highlights advanced nanoparticle-based strategies to improve outcomes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/emerging-nanotherapeutics-for-hpv-associated-cancers-current-advances-challenges-and-future-directions/367809/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/emerging-nanotherapeutics-for-hpv-associated-cancers-current-advances-challenges-and-future-directions/367809.png","ImageObject",300,407,{"name":42,"@type":43},"Elsa","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What HPV-related cancers are discussed in the review?","Question",{"text":63,"@type":64},"The review covers cervical, vulvar, vaginal, and penile cancers, and also includes anal, oral, and oropharyngeal cancers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why are traditional therapies considered limited for HPV-associated cancers?",{"text":68,"@type":64},"Conventional treatments can have drawbacks such as lack of specificity for tumor cells and harmful effects on non-tumor cells.",{"name":70,"@type":61,"acceptedAnswer":71},"How do nanotherapeutics aim to improve treatment outcomes?",{"text":72,"@type":64},"Nanotherapeutics support precise drug delivery and can be combined with modalities like immunotherapy or gene therapy to enhance therapeutic effectiveness.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367809,1790199709,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},137455077381,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Review  \nEmerging nanotherapeutics for HPV‑associated cancers: current advances, challenges, and future directions  \nUjjawal Sharma1 · Himanshu Shekhar1 · Bunty Sharma2 · Anidrisha Sahu1 · Shafiul Haque3,4 · Darin Mansor Mathkor3 · Damandeep Kaur5 · Hardeep Singh Tuli6 · Astha Mishra7 · Faraz Ahmad8  \nReceived: 26 November 2024 / Accepted: 21 April 2025  \n© The Author(s) 2025 OPEN  \nAbstract  \nHuman Papillomavirus or HPV are viruses belonging to the family Papillomaviridae, these have double-stranded circular DNA. HPV is among the most common sexually transmitted infections which affect over 50% of the adult population. It is also responsible for approximately 5% of total cancer cases. The cancers associated with HPV include cervical cancer, vulvar cancer, vaginal cancer in females, and penile cancer in males. Apart from genital cancer, it also causes other cancers, such as anal cancer, oral cancer and oropharyngeal cancer. Traditional therapeutic methods like surgery, chemotherapy, radiotherapy, and others come with many drawbacks, such as non-specificity towards tumorous cells and other harmful effects on other non-tumorous cells. Advancement in nanotherapeutics has enabled us to precisely target cancer cell for better therapeutic outcome. These nanoparticles help in precise drug delivery, and they can also be combined with other treatments like gene therapy or immunotherapy for better results. This review synthesizes findings from PubMed and Scopus databases using keywords such as “nanoparticles”“HPV” and “cancer” to provides a comprehensive overview of HPV-related cancer, their current treatment approaches and their limitations, and advanced nanotherapeutic approaches for HPV-related cancers such as targeted drug delivery using nanoparticles, nanoparticle-mediated radiotherapy, immunotherapy, and gene therapy. Our review findings suggest that advanced nanotherapeutics have the potential to significantly enhance therapeutic outcomes in HPV-related cancers.  \nKeywords HPV · Nanotherapeutics · Cervical cancer · Oropharyngeal cancer · Targeted drug delivery · Radiosensitization  \n1 Introduction  \nHuman papillomaviruses (HPVs) are ds DNA viruses. HPV primarily spreads through direct contact between the skin or mucous membranes and it enters the body through cuts or abrasions. HPV infection is the most prevalent sexually transmitted infection affecting every second sexually active adults of both genders. HPV can lead to various  \n* Hardeep Singh Tuli, [hardeep.biotech@gmail.com](hardeep.biotech@gmail.com); * Faraz Ahmad, [faraz.ahmad@vit.ac.in |](faraz.ahmad@vit.ac.in |1Department of Human Genetics)[1](faraz.ahmad@vit.ac.in |1Department of Human Genetics)[Department of Human Genetics](faraz.ahmad@vit.ac.in |1Department of Human Genetics)  \n[and Molecular Medicine](and Molecular Medicine), [Central University of Punjab](Central University of Punjab), [Bhatinda 151001](Bhatinda 151001), [India](India). 2Department of Biotechnology, Graphic Era (Deemed  \nto Be University), Dehradun, Uttarakhand, India. 3Department of Nursing, College of Nursing and Health Sciences, Jazan University, Jazan, Saudi Arabia. 4School of Medicine, Universidad Espíritu Santo, Samborondón 091952, Ecuador. 5University Center for Research & Development (UCRD), Chandigarh University, Gharuan, Mohali, Punjab, India. 6Department of Bio-Sciences and Technology, Maharishi Markandeshwar Engineering College, Maharishi Markandeshwar (Deemed to Be University), Mullana, Ambala 133207, India. 7Department of Optometry, Chitkara School of Health Sciences, Chitkara University, Punjab, India. 8Department of Biotechnology, School of Bio Sciences and Technology (SBST), Vellore Institute of Technology, Vellore 632014, India.  \nDiscover Oncology  \n(2025) 16:1653  \n| [https://doi.org/10.1007/s12672-025-02439-w](https://doi.org/10.1007/s12672-025-02439-w)  \nconditions, such as common warts, genital warts, and genital cancer [1] . Broadly, HPVs comprise two groups: lowrisk and hig","cbCaibgyT5fdBVBJ","https://ap.wps.com/l/cbCaibgyT5fdBVBJ","pdf",3659593,15,"English","# Introduction\n# Emerging nanotherapeutics approaches\n## Targeted drug delivery using nanoparticles\n## Nanoparticle-mediated radiotherapy\n## Immunotherapy and therapeutic vaccines\n## Nano-mediated gene therapy (nano-CRISPR)","[{\"question\":\"What HPV-related cancers are discussed in the review?\",\"answer\":\"The review covers cervical, vulvar, vaginal, and penile cancers, and also includes anal, oral, and oropharyngeal cancers.\"},{\"question\":\"Why are traditional therapies considered limited for HPV-associated cancers?\",\"answer\":\"Conventional treatments can have drawbacks such as lack of specificity for tumor cells and harmful effects on non-tumor cells.\"},{\"question\":\"How do nanotherapeutics aim to improve treatment outcomes?\",\"answer\":\"Nanotherapeutics support precise drug delivery and can be combined with modalities like immunotherapy or gene therapy to enhance therapeutic effectiveness.\"}]","Emerging nanotherapeutics for HPV-associated cancers: current advances, challenges, and future directions | PDF",1790172783,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/16b4fac38b145ba24f895e0dbbfc9246.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe212be214b542fd1fdb7f4071a04126.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/675ec65fc2f73bb2aafc85d30f439a47.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/41b1dd2c1232e8d0e2ae4ca4b790035c.webp",980,1301]